Skip to content
Men Under Microscope – Lifestyle
Author:
IGC Pharma, Inc.
IGC Pharma Reports Third Quarter 2026 Financial Results and Provides Business Update
November 9, 2026
IGC Pharma’s Alzheimer’s Agitation Drug Candidate Now Patented in the U.S., Canada, and Mexico as Phase 2 Readout Nears
November 5, 2026
IGC Pharma Unveils PRISM AI Platform to Move Alzheimer’s Risk Prediction to Brain-Health Action and Commercial Deployment
October 13, 2026
IGC Pharma Completes Enrollment in Phase 2 CALMA Alzheimer’s Trial; Topline Results Expected Q4 2026
September 28, 2026
IGC Pharma Reports Q2 2026 Results as CALMA Alzheimer’s Trial Moves Within Six Randomizations of Enrollment Closure
August 18, 2026
IGC Pharma Strengthens Regulatory Readiness as Phase 2 CALMA Alzheimer’s Trial Approaches Enrollment Closure and Q4 Topline Readout
August 11, 2026
IGC Pharma Evaluates Potential Recovery Options as Federal Jury Verdict Brings Renewed Attention to 2018 IGC Short Campaign
July 29, 2026
IGC Pharma to Showcase AI Portfolio at AAIC 2026, Including AHA Platform That Reduced Alzheimer’s Data Harmonization Time by 90% in Representative Workflow
July 9, 2026
IGC Pharma CEO and Principal Financial Officer Purchase More Than $1.15 Million of Common Stock Directly from the Company
July 7, 2026
IGC Pharma’s AHA Agentic AI Platform Reduces Alzheimer’s Data Harmonization Time by 90% in Representative Workflow
June 23, 2026
1
2
Next Page
→